[ad_1]
Albert Bourla, CEO of the US pharmaceutical giant Pfizer, said in a video posted today: “Today is a historic day, today is a historic day for science and for all of us.”
“It has been 248 days from the day we announced our plans to cooperate with BioNTech, until the request we made today to the US Food and Drug Administration,” Bourla said in his message.
Albert Bourla continued: “From concept to license applications, we have worked at an extraordinary pace in our clinical development program, always maintaining our focus on safety.”
Pfizer was the first company in the US to apply for a coronavirus vaccine license. According to the statement made today by Pfizer and BioNTech; The candidate vaccine, known as ‘BNT 162b2’, could potentially be used in high-risk population groups in the US in mid-December.
MINISTER KOCA: 1 MILLION DOSE WILL COME IN THE FIRST STAGE
class = “cf”>
The Health Minister’s husband Fahrettin said that the coronavirus vaccine can be licensed first in Turkey in December and announced that 1 million doses will be supplied.
Fahrettin Koca, Prof. Dr. Uğur Şahin and Dr. Özlem Türeci added that the vaccine developed by the BioNTech company, managed by the couple, could increase the supply to 25 million doses by 2021.
The application to the US Drug Administration is based on the results of phase 3 clinical trials of the vaccine. Vaccine trials began in the US on July 27, and more than 43,000 people were tested in the process.
Based on the final analysis obtained from the tests, the BioNTech / Pfizer vaccine was 95 percent effective in preventing coronavirus. The vaccine is also effective in the elderly and has no serious side effects.
It was stated that in the phase 3 vaccine trials, 42 percent of global participants from diverse backgrounds and 30 percent of participants from the United States participated in caring for race and ethnicity.
